Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Verapamil

Verapamil

Calcium channel blocker (non-DHP, AV-node active)

AdultCCBNon-DHPRate controlAnginaHTN

Indication

Rate control β€’ angina β€’ selected HTN

At a glance

INDICATIONS (CORE USE)

Rate-control pathways, angina, and selected HTN uses.

ADULT DOSE (STANDARD)

Oral dosing titrated by HR/BP and tolerability; route/formulation specific.

MAX DOSE

Formulation/protocol-specific.

Route

PO predominant; monitor conduction effects closely

PEDIATRIC DOSE

Specialist only.

Do not miss

Must-not-miss safety points

Major warning

- Bradycardia / AV block risk - Constipation is common and clinically relevant

Indications

USE IF: selected rate-control, angina, and HTN pathways. AVOID IF: symptomatic bradycardia, high-grade AV block, or clinically inappropriate HFrEF use.

Primary

  • Rate-control pathways
  • Angina
  • Hypertension (selected contexts)

Dosing

STANDARD (ADULT PO)

Titrate cautiously with conduction/hemodynamic surveillance.

ADULT DOSE

Dose to HR/BP and symptom tolerance; formulation-specific.

PEDIATRIC DOSE

N/A

MAX DOSE

By formulation/protocol.

Practical Note

Assess constipation burden early and proactively in follow-up.

Warnings

Clinical warnings

  • Bradycardia/AV-conduction suppression risk is clinically significant.
  • Negative inotropy/conduction slowing warrants caution in HFrEF contexts.
  • Constipation is high-yield with verapamil and should be anticipated.

Contraindications

  • Symptomatic bradycardia
  • High-grade AV block (without pacing)
  • Clinically inappropriate HFrEF context

Drug interactions

  • Beta-blockers or other AV-node blockers: severe bradycardia / AV block / shock risk
  • Digoxin (especially with verapamil): level rise and AV-block/bradycardia risk
  • CYP3A4/P-gp interaction burden can be clinically significant
  • Digoxin and AV-node blocker interactions can be clinically dangerous.

Special populations

Pediatrics

Specialist only.

Pregnancy

Specialist-guided use only when clearly indicated.

Lactation

See lactation references and product labeling.

Renal impairment

Monitor clinical response and hemodynamics.

Hepatic impairment

Hepatic impairment can increase exposure; slower titration needed.

Elderly

Conduction/hypotension adverse effects can be more pronounced.

Administration

Route/formulation-aware prescribing with interaction review at each change.

Monitoring

  • Monitor: - Monitor HR + BP and symptomatic bradycardia (fatigue, presyncope) - Use stronger caution in HFrEF or baseline conduction disease
  • Recheck: - Reassess ECG/AV-conduction risk when clinically indicated
  • Hold if:
    - HOLD if HR <50 with symptoms, high-grade AV block signs, or marked hypotension

Overdose / toxicity

Clinical Picture

A) Mild β†’ dizziness, fatigue, bradycardia B) Moderate β†’ hypotension + bradycardia/AV delay, conduction symptoms, hyperglycemia trend C) Severe β†’ shock, high-grade AV block, refractory toxicity

Immediate Actions

β€’ Airway + continuous monitoring (ABC, BP, telemetry) β€’ Hypotension β†’ IV fluids first-line β€’ Refractory hypotension β†’ early vasopressors β€’ Severe toxicity β†’ IV calcium + HIET + toxicology/ICU escalation β€’ Stop CCB immediately

Antidote

- No single antidote - CCB toxicity support β†’ IV calcium, vasopressors, HIET (protocol-guided) - Bradycardia / conduction compromise β†’ pacing when clinically indicated - Refractory severe toxicity β†’ ECMO consideration (center-dependent) - IV lipid β†’ selective toxicology-guided use

Decontamination

β€’ Recent oral ingestion β†’ activated charcoal if protected airway and early presentation (toxicology-guided)

Escalation

- Refractory shock / severe conduction toxicity β†’ ICU + toxicology - Persistent instability despite calcium + vasopressors β†’ HIET / pacing / ECMO pathway

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Verapamil identity: interaction-heavy non-DHP with high constipation burden.

Clinical pearls

Do not combine casually with beta-blockers or digoxin without conduction-risk planning.

CCB safety

    Pharmacokinetics

    Formulation-dependent kinetics; interaction burden is high-yield.

    Mechanism of action

    Non-DHP calcium channel blockade with strong nodal/conduction effects.

    Common brand names

    Saudi Arabia

    Isoptin, Calan

    Global

    (placeholder β€” verify local formulation)

    Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

    Country practice notes

    Global data (no country-specific data available)

    • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
    • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

    References

    Saudi Arabia

    • SFDA (Saudi Food & Drug Authority)
    • Saudi National Formulary / MOH (where available)

    International

    • WHO Model List of Essential Medicines (verify current edition)
    • US FDA or EU EMA product information (when national SmPC is unavailable)
    • ACC / AHA HTN/arrhythmia/HF guidance
    • ESC AF and chronic coronary syndrome guidance where relevant
    • FDA / SFDA product labeling

    Do not miss

    • Bradycardia / AV block risk
    • HFrEF caution / avoid when clinically inappropriate
    • Beta-blocker or AV-node blocker combinations can cause severe bradycardia/shock
    • Hypotension risk with conduction suppression